Gilead Foundation Commits Over $3 Million to Address Food Insecurity

Commitment Extends Support to Rising Need in California, North Carolina, New Jersey, Maryland, and Washington, D.C. –

Gilead Foundation today announced that it has committed over $3 million in grants to expand access to food in communities across the United States. Gilead Foundation Healing Hunger awards will enable 14 regionally focused organizations to meet the unique needs of their communities by improving long-term nutrition access. The funding, distributed through the Gilead Foundation, supports organizations addressing food insecurity in California, North Carolina, New Jersey, Maryland, and Washington, D.C.

The funding focuses on reducing barriers to fresh food in vulnerable communities where food insecurity rates remain highest. Funding supports innovative food sourcing and distribution models, and integrated services to connect families with nutrition education, workforce training, and benefits enrollment.

"There is a deep connection between food security and health," said Shreya Jani, Senior Vice President of Public Affairs, Gilead Sciences and Board Member, Gilead Foundation. "Food insecurity is linked to a wide range of health risks, including chronic conditions, infectious diseases, and other serious illnesses. Through Gilead Foundation Healing Hunger, we are partnering with organizations that provide education, infrastructure, training and more to make a real impact and improve health outcomes."

Food insecurity is closely tied to poorer health outcomes, including diabetes, hypertension, obesity, and depression, as well as developmental delays and long-term health issues for children. The Gilead Foundation grants will be used to pilot and scale solutions including mobile pantries, produce recovery efforts, urban farming initiatives, and school-centered distribution programs, with the goal to strengthen local food systems and improve food stability for families.

"The California Association of Food Banks, in partnership with the five Bay Area food banks, is grateful for the Gilead Foundation's investment in our collaborative sourcing model," said Stacia Hill Levenfeld, Chief Executive Officer, California Association of Food Banks. "This funding will expand access to culturally relevant food, strengthen local food systems, and improve long-term community health."

Key Facts:

  • USDA data shows that adults in very low food-secure households experience substantially higher rates of chronic conditions, including hypertension (36.4% vs. 29.1%) and diabetes (9.6% vs. 4.3%).
  • Additional USDA analysis from 2019–22 found that the predicted prevalence of key chronic diseases was 1.9 to 9.5 percentage points higher among adults in very low food-secure households compared with those in high food-secure households.
  • Children living in food-insecure households face significantly worse health outcomes, including higher rates of asthma and depressive symptoms, nearly double the likelihood of emergency department visits, and a 179% increase in forgone medical care, underscoring the urgent need to address food insecurity as a public health priority.

Grant recipients include:

  • California Association of Food Banks Bay Area Collaborative including the San Francisco-Marin Food Bank, Alameda County Community Food Bank, Second Harvest of Silicon Valley, Food Bank of Contra Costa and Solano, and Redwood Empire Food Bank to scale an equity-driven sourcing model that distributes 1.2 million pounds of culturally relevant produce while lowering food bank costs and supporting minority-owned farms.
  • Los Angeles Regional Food Bank to support a year-round mobile pantry program delivering 2.5 million pounds of food to communities across Los Angeles County.
  • Social Justice Learning Institute to distribute 850,000 pounds of fresh produce while expanding community-led education and urban farming efforts in Inglewood, CA.
  • Food Forward to aid a produce recovery program that redirects 833,000 pounds of fresh food and reduces waste and emissions in Southern California.
  • Food Bank of Central and Eastern North Carolina to support the distribution of 17 million pounds of food through 600 partner agencies.
  • Community Food Bank of New Jersey to deliver 2.28 million pounds of food to children while expanding workforce training and benefits enrollment programs.
  • Interfaith Food Pantry Network to support 2.3 million pounds of year-round food distribution and food recovery efforts for families in Morris County, NJ.
  • Capital Area Food Bank to expand Mobile Market sites in Washington, DC and to provide more than 1.2 million pounds of food through 170 schools.
  • Maryland Food Bank to support school pantries that deliver 2.4 million pounds of food through 170 schools.

The Gilead Foundation's investment in Gilead Foundation Healing Hunger is part of its broader commitment to supporting communities where Gilead employees live and work. In 2024, the Foundation contributed $21.5 million to organizations committed to advance programs that promote education, health equity, and community resilience.

About the Gilead Foundation

The Gilead Foundation is a nonprofit organization that works to create a thriving health ecosystem. The Gilead Foundation takes a holistic approach to mitigate the root causes of health inequities by providing resources to organizations that empower people with the skills to be their own best advocate and create systems of support that strengthen communities, classrooms and workplaces.

About Gilead Sciences

Gilead Sciences, Inc. (Nasdaq: GILD) is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer and inflammation. In 2025, Gilead announced a planned $32 billion investment to further strengthen its U.S. footprint to power the next era of discovery, job creation and public health preparedness – while continuing to invest globally to ensure patients everywhere benefit from its scientific innovation. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, Calif.

Gilead and the Gilead logo are trademarks of Gilead Sciences, Inc., or its related companies.

For more information about Gilead, please visit the company's website at www.gilead.com , follow Gilead on X/Twitter (@Gilead Sciences) and LinkedIn (@Gilead-Sciences).

Samantha Stokes-Granberry, Media
public_affairs@gilead.com

Jacquie Ross, Investors
investor_relations@gilead.com

News Provided by Business Wire via QuoteMedia

GILD
The Conversation (0)
Appoints global biopharma leader Paul Carter as Non-Executive Director to support next phase of strategic growth

Appoints global biopharma leader Paul Carter as Non-Executive Director to support next phase of strategic growth

Solvonis Therapeutics plc (LSE: SVNS), an emerging biopharmaceutical company developing novel medicines for high-burden central nervous system ("CNS") disorders, is delighted to announce the appointment of Paul Carter as Non-Executive Director, effective 27 October 2025.Paul Carter is a highly... Keep Reading...
CHMP Adopts Positive Opinion Recommending Hepcludex®  for Full Marketing Authorization for the Treatment of Hepatitis Delta Virus

CHMP Adopts Positive Opinion Recommending Hepcludex® for Full Marketing Authorization for the Treatment of Hepatitis Delta Virus

-- If Granted by the European Commission, Hepcludex will Become the Only Approved Treatment for HDV in the EU -- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive... Keep Reading...
Gilead Remains Steadfast in Support for Hepatitis C Elimination Efforts

Gilead Remains Steadfast in Support for Hepatitis C Elimination Efforts

The recent national conversation on hepatitis C (HCV) is an encouraging step towards viral hepatitis elimination in the U.S. With its long history of leadership in viral hepatitis, Gilead continues to support efforts that focus on HCV elimination. Gilead is proud that its medicines have treated... Keep Reading...
Gilead Sciences Announces First Quarter 2023 Financial Results

Gilead Sciences Announces First Quarter 2023 Financial Results

Product Sales Excluding Veklury Increased 15% Year-Over-Year to $5.7 billion Biktarvy Sales Increased 24% Year-Over-Year to $2.7 billion Oncology Sales Increased 59% Year-Over-Year to $670 million Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the first... Keep Reading...
Gilead Sciences Releases Inaugural ESG Impact Report

Gilead Sciences Releases Inaugural ESG Impact Report

Gilead Sciences recently released its inaugural Environmental, Social and Governance (ESG) Impact Report. This is an evolution of our traditional Year in Review, and uses the ESG framework to highlight the successes and achievements of the prior yearThough the report itself is new, our... Keep Reading...
Quantum Biopharma

Quantum BioPharma Announces Cash Reward of up to USD $7Million for Proof of Market Manipulation in its Stock

Reward to be Paid if Information Contributes Significant Evidence Leading to a Trial Victory or Settlement in Landmark USD $700 Million+ Lawsuit

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol... Keep Reading...
Imagion Biosystems

Phase 2 HER2 Clinical Trial Manufacturing Commenced, WSU Imaging Optimisation Program Underway

Imagion Biosystems (ASX: IBX) (Company or Imagion), a company dedicated to improving healthcare outcomes through the early detection of cancer utilising its proprietary MagSense® imaging technology, is pleased to provide shareholders with a progress update regarding the Company’s business and... Keep Reading...
Stethoscope on stacked gold coins, symbolizing healthcare costs or medical finance.

Trump Tariffs to Raise US Medical Device Costs, Hospitals Hold Off on Stockpiling

President Donald Trump’s new round of tariffs —this time targeting copper— has intensified concerns about rising costs across key sectors, including healthcare. But despite significant price pressures on steel, aluminum, and now copper, all vital to medical device production, there is no... Keep Reading...
Actinogen

Actinogen confirms 100th participant in XanaMIA phase 2b/3 Alzheimer’s disease trial and interim analysis timeline

Actinogen Medical ASX: ACW (“ACW” or “the Company”) is pleased to announce that the 100th participant in its pivotal XanaMIA phase 2b/3 randomized trial of Xanamem® for Alzheimer’s disease (AD) has now passed all screening tests and is scheduled for randomization and treatment in July. This... Keep Reading...
Emyria Limited

Medibank to Fund Emyria’s PTSD Program at Perth Clinic

Emyria Limited (ASX: EMD) (“Emyria”, or the “Company”) a leader in developing and delivering innovative mental health treatments, is pleased to announce that Medibank Private Limited (“Medibank”), Australia’s largest private health insurer, has commenced funding for eligible customers to access... Keep Reading...
ASX:HIQ

HITIQ Announces Exclusive Global Agreement with Shock Doctor for PROTEQT Instrumented Mouthguard

Common Shareholder Questions – Entitlement Offer

HITIQ Limited (ASX: HIQ) (HITIQ or the Company), a pioneer in concussion management, proudly announces an exclusive global agreement with Shock Doctor, the world’s leading mouthguard innovator. This landmark agreement marks Shock Doctor’s two-year effort to design a mouthguard that will... Keep Reading...

Latest Press Releases

Related News